Skip to content

Released Aug 4, 2023, before the open

10-Q filed Aug 4, 2023, 35 days after period end · 0001628280-23-027402

Q2 2023 · 10-Q
Revenue$5.60M+24.7% vs Q2 2022+5.5% vs Q1 2023
Net Income-$29.49MN/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.70N/M vs Q2 2022N/M vs Q1 2023
Operating Income-$32,050,000N/M
Operating Cash Flowderived-$32,175,000N/M
Free Cash Flowderived-$32,644,000N/M
Margins · derived
Operating margin-572.4%+77.6 pt vs Q2 2022
Net margin-526.6%+81.7 pt vs Q2 2022

What the release said

The release

Same quarter

MetricQ2 2023Q2 2022Q2 2021Q2 2020
Revenue$5.60M$4.49M$279.00K$0.00
Net Income-$29.49M-$27.31M-$23.11M-$15.72M
EPS Diluted-$0.70-$0.66-$0.63-$2.90

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR